Molecular Partners AG ADR Company Profile
NASDAQ: MOLNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Molecular Partners at a glance
Molecular Partners AG ADR (NASDAQ: MOLN) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Schlieren, Switzerland. Molecular Partners is led by Dr. Patrick Amstutz Ph.D. and employs about 134 people. The company's shares have traded publicly since 2021.
At a market capitalization of $96.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001745114, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Molecular Partners do?
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Business description based on the company's public filings.
Company information
- Legal name
- Molecular Partners AG ADR
- Ticker
- NASDAQ: MOLN
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Patrick Amstutz Ph.D.
- Employees
- 134
- Headquarters
- Wagistrasse 14, Schlieren, Switzerland
- Phone
- 41 44 755 77 00
- Website
- molecularpartners.com
- IPO year
- 2021
- Market cap
- $96.03M
- SEC CIK
- 0001745114
Companies similar to Molecular Partners
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs MOLN |
| VYGRVoyager Therapeutics Inc. | 1.53 | -4.97% | $95.21M | vs MOLN |
| OTLKOutlook Therapeutics Inc. | 0.39 | -2.74% | $94.94M | vs MOLN |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs MOLN |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs MOLN |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs MOLN |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs MOLN |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs MOLN |